News

The $100m facility, which will be operated by the company’s subsidiary TOT Biopharm, will produce anti-cancer drug injections. In addition, the company’s other new facility producing anti-cancer injections,

Curis president and chief executive officer Dan Passeri said the GDC-0917 agreement adds depth to current pipeline of proprietary targeted anti-cancer agents and further solidifies the company’s relationship

Under the deal, CoreRx will integrate its expertise in problem-solving and formulation/processing of small molecules with Viropro’s specialization in the development and manufacturing of biopharmaceutical drugs to provide

According to the development and commercialization deal signed between the firms, NDA acceptance by the FDA has triggered a milestone payment worth $15m to AVEO from Astellas. The

Evotec will support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors by running and validating its existing as well as developing biological assays. Evotec chief operating

According to the deal, Beactica will leverage Sprint drug discovery platform in identifying allosteric modulators against certain central nervous system proteins for supporting the Janssen’s discovery efforts. The

Through the acquisition, Pfizer has gained exclusive North American commercialization rights to the FDA approved Quillivant XR. Quillivant XR (methylphenidate hydrochloride) extended-release oral suspension is indicated to treat

The sale of Bioserv will support NextPharma’s growth strategy of focusing on its core specialty and conventional product and technology operating platform in Europe. KESA Partners managing partner

Pursuant to the deal, Sanofi gains license to develop an immunotherapy to stop immune responses provoked by a food allergen. Sanofi also has a choice to develop two